Tarsus Pharmaceuticals
Tarsus Pharmaceuticals invites interested candidates to join their talent community, allowing them to submit a résumé and brief information for future consideration. The company highlights upcoming growth opportunities and encourages following their LinkedIn for updates.
Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel therapies for diseases with high unmet need, with a primary focus on eye care. The company markets XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment for Demodex blepharitis, and has a pipeline targeting conditions such as ocular rosacea and Lyme disease.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.